TABLE 2

Single-dose pharmacokinetics of parent silybin A and silybin B

Results are shown as geometric mean (95% confidence interval), except for T_max, which is shown as median (minimum, maximum). Data are for n = 6 subjects.

Cohort	PK Parameter	SA		SB
Cohort	PK Parameter	HCV	NAFLD	HCV	NAFLD
280 mg	AUC_{0–8 h} (ng · h/ml)	201 (115–338)	228 (75–469)^{^a}	93 (15–188)^{^b}	80 (70–91)^{^a}
	C_max (ng/ml)	78 (32–147)	82 (35–153)^{^a}	27 (8–50)^{^b}	30 (16–53)^{^a}
	T_max (h)	2.0 (1.0, 4.0)^{^b}	2.0 (1.0, 6.0)^{^a}	3.0 (1.0, 4.0)^{^b}	2.0 (2.0, 6.0)^{^a}
	t_1/2 (h)	1.3 (0.7–2.0)	1.8 (−2.2–7.6)	0.9 (−0.9–6.3)^{^b}	1.8 (−1.6–6.6)
560 mg	AUC_{0–8 h} (ng · h/ml)	557 (470–657)	859 (508–1397)	125 (94–160)^*^,^{^a}	261 (164–395)
	C_max (ng/ml)	192 (147–250)	275 (127–491)	58 (31–92)^{^a}	93 (55–145)
	T_max (h)	1.5 (1.0, 4.0)	2.7 (1.5, 4.0)	1.5 (0.5, 4.0)^{^a}	2.7 (1.0, 4.0)
	t_1/2 (h)	1.4 (0.9–2.1)	1.4 (0.8–2.3)	1.1 (0.7–1.7)^{^a}	1.5 (0.6–2.9)

SA, silymarin A; SB, silymarin B.
↵* p < 0.05.
↵a n = 5.
↵b n = 4.